KaloBios Pharmaceuticals (“KBIO”)… $150 per share or bust? A Dispassionate Analysis

(December¬†7th, 2015) Few stories in biotech this quarter have captured the imagination of the retail investing crowd like¬†KaloBios Pharmaceuticals, Inc. (Nasdaq: “KBIO”). This stock was trading for pennies and headed for a bankruptcy liquidation when former Retrophin CEO Martin Shkreli and a buying group bought more than 70% of the common stock of KBIO on the open market in a matter of days and immediately took control of the company. The resulting news of Martin Shkreli’s purchase and subsequent appointment as Chief Executive Officer sent the stock soaring skywards. On the first day of trading it closed at $10.40 and within two days after that it touched $40. Read more

Intra-Cellular Therapies (“ITCI”) Stock Soars While Key Clinical Data Not Presented to Shareholders Looks Highly Disappointing

(July 15th, 2015) Biotech stocks have been on fire. And for good reason as numerous life-saving discoveries have come out of small, previously-unknown firms, making their owners rich many times over. But beneath the surface, a number of troubling drug development companies have caught the attention of investors with clinical data that’s dubious at best. With seemingly endless amounts of optimism, these biotech stocks have ridden the wave of investor enthusiam even when the data doesn’t look as promising as the market caps seem to indicate.

Read more

All You Ever Wanted to Know About Retrophin But Were Afraid to Ask

(June 2nd, 2014) Humans, like atoms, abhor unsteady states of existence. Just like electron transport gravitates towards a steady-state, people gravitate towards peaceful lands and away from battleground areas. Read more

#

Little Bear Research is a firm that uncovers information for investors interested in reality over perception.

 

 

 

” Concentration is my motto – first honesty, then industry, then concentration. ” — Andrew Carnegie